[ad_1]
Dr. Lindsey Marshall joins Haute Beauty Network as a smile expert representing the Philadelphia market.
(PRWeb December 07, 2021)
Read the full story at https://www.prweb.com/releases/smile_expert_dr_lindsey_marshall_joins_exclusive_haute_beauty_network/prweb18376336.htm
[ad_2]
[ad_1]
Holt PPE partners with See Me Clear™ to offer customers a revolutionary PPE product for maintaining line of sight communication while protecting the wearer from bacteria.
CHARLOTTE, N.C. (PRWEB)
December 07, 2021
Holt PPE, a Certified Women-owned business, has partnered with See Me Clear™, a 3-ply, anti-fog clear lens mask manufacturer, to bring you a product that ensures inclusion and equitable outcomes for people who rely on supplemental lip and facial gestures to fully comprehend spoken communication.
Pat Holt, the owner of Holt PPE, has been a nurse for over 30 years and understands and appreciates the importance of being able to see lip and facial movements in order to fully comprehend conversation and instruction. These masks are very popular in healthcare, customer facing, working with geriatric and pediatric populations or any other time where it’s beneficial to see facial features while communication.
Each See Me Clear™, mask is constructed from PPE, quality assured materials and meets all ASTM Level 1 standards, guaranteeing a minimum of 95% bacterial filtration efficiency (BFE).
The high quality See Me Clear™ masks are perfect for everyday use. They allow you to stay productive and confident while getting more done. Visit the following website, http://www.seemeclear.com, for more information on this innovative mask.
Holt PPE, is so confident that you will love the See Me Clear™ masks, that we would like to offer one free box for your organization for review. If you would like to receive a complimentary sample, please email info@holtppe.com with your mailing address or visit http://www.holtppe.com to learn more about pricing and product details.
Contact
Patricia Holt
info@holtppe.com
704-634-9591
Share article on social media or email:
[ad_2]
[ad_1]
Arpy Kothari, PA-C
“We are excited for Ms. Kothari to join Board-Certified Dermatologist Hans Sander, M.D. in our Jollyville location,” stated U.S. Dermatology Partners Chief Executive Officer Paul Singh. “Her addition to this office furthers our commitment to expanding patient access to high-quality care.”
AUSTIN, Texas (PRWEB)
December 07, 2021
U.S. Dermatology Partners is pleased to welcome new dermatology Physician Assistant, Arpy Kothari, M.S., PA-C to their Jollyville clinic in Austin, Texas.
Arpy received her Bachelor of Arts in Cell Biology and Neuroscience from Rutgers University in Piscataway, NJ, and earned her Master of Science in Physician Assistant Studies from Baylor College of Medicine in Houston. She has over 16 years of clinical experience in emergency medicine, cardiology, neurology, and dermatology. Prior to moving to Austin, Arpy worked in dermatology groups throughout New Jersey and New York.
Board-certified by the National Commission on Certification and a member of the American Academy of Physician Assistants, Arpy brings a wide range of clinical expertise to U.S. Dermatology Partners. This includes advance knowledge in general medical dermatology and skin conditions such as acne, warts, seborrheic dermatitis, cysts, eczema, dermatitis, and skin cancer.
“We are excited for Ms. Kothari to join Board-Certified Dermatologist Hans Sander, M.D. in our Jollyville location,” stated U.S. Dermatology Partners Chief Executive Officer Paul Singh. “Her addition to this office furthers our commitment to expanding patient access to high-quality care.”
Arpy looks forward to continuing her passion for providing quality, patient-centered care and is currently accepting new patients. To schedule an appointment, please call 512-345-8688.
About U.S. Dermatology Partners
As one of the largest dermatology practices in the country, U.S. Dermatology Partners patients not only have access to general medical, surgical, and cosmetic skin treatments through its coordinated care network but also benefit from the practice’s strong dermatology subspecialty thought leaders and medical advisory board. To be the best partner to its patients, U.S. Dermatology Partners is fervently focused on providing the highest level of patient-first care, and its team, therefore, includes recognized national leaders in areas such as clinical research, psoriasis, and Mohs Surgery. To learn more, visit usdermatologypartners.com.
Share article on social media or email:
[ad_2]
[ad_1]
“I am very honored to have been chosen to help women move forward in leadership positions,” shared Shawna. “This will afford women the opportunity to better understand how to go about developing their own leadership skills thus allowing them the opportunity to advance.”
SARASOTA, Fla. (PRWEB)
December 07, 2021
Dental Care Alliance proudly announces that Shawna Eury, Division Vice President for Florida and an Ally since 2009, has been appointed to the Board of Directors for Women in DSO®. Founded in 2020, Women in DSO® is the official nonprofit organization supporting the empowerment and growth of women leaders in dental support organizations. The group’s mission is to highlight and support contributions of women in dental support organizations and to provide a platform to advance women in leadership.
Shawna began her career with DCA in 2009 as a Patient Service Representative, and today oversees eighty practices and leads seven regional managers in the state of Florida. Shawna consistently focuses on collaborating with the field and offering guidance to empower the team to continue to strive for success.
“I am very honored to have been chosen to help women move forward in leadership positions,” shared Shawna. “This will afford women the opportunity to better understand how to go about developing their own leadership skills thus allowing them the opportunity to advance.”
Shawna consistently focuses on collaborating with the field and offering guidance to empower the team to continue to strive for success. Considering Shawna’s journey, it is no surprise she has a passion for unleashing career potential and nurturing continued growth of team members wanting to move to the next level. “Shawna exemplifies DCA’s values and her rise through the field organization is inspiring – she has truly Unleashed her Potential,” said James Nick, Chief Revenue Officer and Chair of DCA’s Diversity, Equity, and Inclusion Council. “We are proud to have her on the leadership team and representing Dental Care Alliance on the board of this important industry organization. I am confident she will help drive success and development of women leaders at DCA and across the industry.”
Dental Care Alliance previously announced that they have joined the Women in DSO® organization as a founding group member. Founding members, partners and progressive DSOs will join Women in DSO® this March 9-11, 2022 at the Aria Resort and Casino in Las Vegas for the inaugural event. To learn more visit https://womenindso.org/official-launch-event.
Dental Care Alliance’s mission is to advance the practice of dentistry by partnering with and supporting dental professionals to create a lifetime of healthy smiles. DCA currently supports over 360 allied practices with more than 775 dentists across 21 states. DCA’s allied practices represent all dental specialties and treat patients under more than 115 brand names.
Share article on social media or email:
[ad_2]
[ad_1]
We’re introducing this to a wider audience because we are convinced from our own experience that the nourishing impact of L-arginine can support nerve health, improve sensation, and relieve the numbness, pain, and tingling of peripheral neuropathy.
SAUSALITO, Calif. (PRWEB)
December 07, 2021
California-based Neuropathy Research Inc. announced the release of its L-arginine-based topical cream designed to relieve the symptoms of peripheral neuropathy (PN). PN refers to pain, tingling, and numbness in the feet or hands suffered by as many as 30 million Americans, the majority of them diabetics. Causes of PN include diabetes, vitamin B-12 deficiency, excessive alcohol consumption, and age. There is no known cure, and the re-purposed anti-seizure medications commonly prescribed to treat the condition often don’t work or cause unpleasant, sometimes intolerable, side effects.
All that was what company co-founder Tony Cook learned from his doctor, Arlene F. Hoffman, DPM, Ph.D., a veteran podiatrist and medical researcher in San Francisco. “She told me my peripheral neuropathy was idiopathic – meaning cause unknown,” recalls Cook, “and the doctor dispensed a topical formulation that she said had helped the many PN patients in her care.”
It turns out that Dr. Hoffman had studied with a fellow scientist in her youth, Dr. Robert Furchgott, who was awarded a Nobel Prize in 1998 for the discovery of nitric oxide, a molecule essential for nerve function. It was later discovered that L-arginine, a naturally occurring amino acid, increased the production of nitric oxide. This led Dr. Hoffman to begin incorporating L-arginine into her topical treatments for PN.
It worked, explains Dr. Hoffman, because the L-arginine could reach the damaged nerves causing the symptoms, since these spidery or “small-fiber” peripheral nerves were close to the surface of the skin and could therefore be readily nourished. The treatments relieved Cook’s symptoms, and he was impressed enough by the doctor’s logic and scientific explanations that he co-founded a company with a partner to develop a topical cream based on Hoffman’s insights. Explains Cook, a 79-year-old serial entrepreneur, “I wanted to pay it forward and use the formulation to help the many, many others with my condition the way it had helped me.”
The product derived from that development effort is the newly launched Neuro One Nerve Support Cream for Peripheral Neuropathy, a non-prescription formulation containing natural ingredients and manufactured in a California-based cosmeceutical facility that is cGMP compliant, FDA registered, and has earned the USDA’s National Organic Program certification. Every Neuro One ingredient is sourced with care, and the product contains nothing from China.
Unlike competitor foot creams that supposedly relieve PN, Neuro One is not a muscle rub. It has no menthol or CBD that simply masks symptoms instead of supporting essential nerve function. No fragrance or dyes are added, and it contains no capsaicin, which helps some people with neuropathy pain but can cause irritating burning sensations in others.
The product is dispensed in an airless pump bottle to keep bacteria from forming with exposure to the air and to maintain the purity of the natural ingredients. It contains a full 100 ml (3.4 fluid ounces). Apply the cream twice per day, being careful to cover the entire top and bottom of the foot, including all around the ankle. Dr. Hoffman says her patients usually experience relief within a few minutes to a few days; for some, relief can take up to a month.
Adds Cook, “We’re introducing this to a wider audience because we are convinced from our own experience that the nourishing impact of L-arginine can support nerve health, improve sensation, and relieve the numbness, pain, and tingling of peripheral neuropathy.” Neuro One is available on Amazon and can also be purchased online at NeuropathyResearch.com.
About Neuropathy Research Inc.:
Neuropathy Research Inc. is a health products and information company providing insights and self-care solutions for the relief of peripheral neuropathy. Our topical treatment, Neuro One Nerve Support Cream, is a natural formulation containing L-arginine designed to nourish nerves in the feet and hands and stimulate nerve health. For help, visit http://www.NeuropathyResearch.com.
Press Contact:
Tony Cook
tcook@neuropathyresearch.com
Share article on social media or email:
[ad_2]
[ad_1]
“We have witnessed firsthand the positive impact the StarMed Hood has on patients and their recovery, as well as their families. Our goal is to ensure that every patient has access to the StarMed Hood.”
EAST SYRACUSE, N.Y. (PRWEB)
December 07, 2021
After a year on the U.S. market, the Intersurgical StarMed CaStar R Hood is saving lives. The StarMed Hood is now being used in several hospitals and hospital systems across the country with outstanding results.
This hood-based patient interface designed to provide a more comfortable alternative to traditional methods of Continuous Positive Airway Pressure (CPAP) and Non-Invasive Ventilation (NIV) is giving patients in respiratory distress a breath of fresh air. The unique and innovative Intersurgical StarMed CaStar R Hood, a highly effective and comfortable patient interface used to treat patients with life-threatening Acute Respiratory Distress Syndrome (ARDS), was issued an Emergency Use Authorization by the FDA. The hood debuted in the U.S. in response to the surge in demand for ventilatory intervention.
Developed by Intersurgical—a leading global medical device designer, manufacturer, and supplier of a wide range of high-quality products for respiratory support—the StarMed Hood provides a more comfortable and innovative solution for patients struggling to breathe.
The pressurized hood can be used for hypoxemic patients, those with critically low levels of oxygen in their bloodstream, as well as for hypercapnic patients, who have excessive carbon dioxide in the bloodstream. A well-tolerated, comfortable, and lightweight interface that fits over the patient’s head, the StarMed Hood forms a semi-enclosed, pressurized environment that assists the patient’s lungs, making it easier to breathe. In addition, a patient wearing the StarMed Hood can eat, sleep, and communicate normally.
The hood interface reduces the risks associated with traditional methods of CPAP therapy and NIV delivery, such as skin breakdown, lesions, and irritation. Use of the StarMed Hood could also reduce the need for patients to be intubated, a process that requires patients to be put into a medically induced coma and increases risks of infection. Avoiding intubation could reduce overall mortality rates for ARDS patients by as much as 48 percent.
The StarMed Hood has a proven track record of use in Europe over the past 20 years. Before and during the COVID-19 pandemic, hospitals across Europe have successfully utilized the StarMed Hood. In the U.S., the reception has been similarly positive. In recent months, Intersurgical was able to increase production capacity to meet the demand for the hood interface in both the U.S. and European markets, assisting countless patients.
“Our entire team is extremely passionate about the StarMed Hood. We have witnessed firsthand the positive impact the StarMed Hood has on patients and their recovery, as well as their families,” said Intersurgical Vice President Edric Smith. “Our goal is to ensure that every patient has access to the StarMed Hood.”
The Intersurgical StarMed CaStar R NIV Hood is authorized by the FDA for the emergency use of ventilators, ventilator tubing connectors, and ventilator accessories under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1).
About Intersurgical
Intersurgical is a global designer, manufacturer, and supplier of high-quality medical devices for respiratory support. For more than 30 years, Intersurgical has provided innovative healthcare solutions in the U.S., developing products from conception to completion and adhering to the highest industry standards. Known for revolutionary products in the medical community, most notably i-gel®, an innovative airway management device. Intersurgical provides a range of respiratory product solutions for patients and clinicians, offering quality, innovation and choice in respiratory care.
Share article on social media or email:
[ad_2]
[ad_1]
Amy Beckley & Ellen Schell
“I started this company in my basement after my own infertility battle and it has become more than I could have imagined. We are so excited to help women get even better information about their cycles to promote better treatment and ultimately better outcomes.” said MFB Fertility’s founder and CEO
BOULDER, Colo. (PRWEB)
December 07, 2021
Proov, creator of the first and only FDA-cleared PdG-testing kit to educate and empower women about their reproductive health, announces today it raised $9.7 million in Series A Funding. The round was led by Hambrecht Ducera Growth Ventures. Additionally, venture capital firms SteelSky Ventures, WCC Partners, Lightship Capital, GingerBread Capital, and Portfolia FemTech II Fund participated in the round.
The Proov PdG test and its associated patented protocol are the first of its kind to confirm ovulation quality, which pertains to when ovulation happens and hormone levels remain elevated for long enough. Confirming ovulation quality is important when it comes to getting pregnant. Since the launch of its original PdG test, Proov has added other products to its portfolio including Proov Predict & Confirm that includes 2 types of tests to both find the 2 most fertile days and confirm ovulation quality. With Proov, women can better determine both when their ovulation is occurring and whether ovulation is occurring, with hormone levels high enough to provide the best chance at pregnancy that cycle. If Proov indicates there may be an ovulation issue, the user can then go to their doctor earlier to seek treatment to fix the problem.
With its newly launched “Complete” product, which the Series A funding will support, Proov has developed the leading at-home hormone testing suite for the four most critical hormones testable in urine, providing FSH, LH, E1G (estrogen marker) and PdG results to women at home. In combination with its easy to use at-home companion app, Proov Complete, now available at proovtest.com, provides the most comprehensive and affordable at-home hormonal pattern analysis across the menstrual cycle, requiring no expensive external reader device.
“I started this company in my basement after my own infertility battle and it has become more than I could have imagined. We are so excited to help women get even better information about their cycles to promote better treatment and ultimately better outcomes.” said MFB Fertility’s founder and CEO, Amy Beckley. “The patented devices and protocols created by Proov represent a fundamental shift in the information available to women about their hormone wellness, leveraging the power of a smartphone. In combination with our industry leading app, our patented protocols ensure that Proov will continue to offer the most robust and differentiated offering in the at-home female hormone testing space, which we are excited to build on” according to MFB Fertility’s CTO and Patent Counsel Jeffrey Schell. Beckley added: “with this funding, Proov is now poised to help women across life stages reach their goals faster and ultimately live better by increasing accessibility to key diagnostic and hormone health supporting solutions – both at home and in partnership with physicians.”
The Proov Insight App provides an easy to follow protocol, leading to quantitative hormone results associated with Proov products. The protocol concludes with an end of cycle report, explaining overall menstrual cycle results including ovulation quality confirmation, along with suggestions for next steps. The Proov Insight App also stores hormone trends over time. Importantly, the Proov Insight App works with iPhone and Android smartphones without the need for any expensive external device.
“What initially drew us to Proov was their traction in the market, but what has impressed us more is their vision to bring high quality, science-backed products that could have a game-changing impact on women’s health”, said Betsy Hambrecht, of Hambrect Ducera Growth Ventures. “We look forward to our partnership and to bringing better products and solutions to advance women’s health.”
What started as a simple test to confirm ovulation has evolved. Proov now exists to unleash the power of the menstrual cycle and reproductive hormones to help women reach their goals faster, live better, and feel their best. The company is built on its fundamental belief that women are innately powerful and with the right data, they are unstoppable.
To learn more about Proov® and its new Insights App, visit proovtest.com. To learn more about PdG and the benefits of tracking it, visit https://proovtest.com/pages/faq.
About MFB Fertility, Inc.
MFB Fertility, Inc. developed Proov®, an at-home PdG test that measures the presence of progesterone metabolite PdG in urine to help a woman confirm that she has ovulated successfully. Originally co-founded in Boulder, Colo. by two women who both struggled to conceive, MFB Fertility was created to empower women to know more about their menstrual cycles, ovulation health, and PdG levels. Don’t just predict ovulation, Proov it! For more information, please visit https://proovtest.com/.
Media Contact
Kristen Mondshein
kristen@kmmcommunications.com
Share article on social media or email:
[ad_2]
[ad_1]
HUNTINGTON BEACH, Calif. (PRWEB)
December 07, 2021
In the beginning of the pandemic the need for COVID-19 testing hit so fast, many labs had to quickly piece together generic out of the box software systems to accommodate the sheer volume and unique remote site testing taking place. In doing so, they soon found issues that they had to work around. Some common issues they deal with are multi-system communication bugs, inability to efficiently track patient sample pick-up and deliveries, issue resolution, dealing with high volume paper requisition forms causing extensive manual input, data entry errors, all leading to time delays and increased costs.
A company called Req Right seems to have solved all these issues. Req Right is a full stack development company that before the pandemic specialized in developing laboratory centric automated workflow systems. Their systems offered customizable workflows for a variety of test types and enabled their clientele to scale efficiently and cost effectively. “Their history in the laboratory space made is simple for them to quickly pivot into the direction of solving workflow issues for high-volume COVID testing,” says CEO Jeff Merrick.
Req Right is located in Orange County, California and pride themselves on the fact that all of their software is created and managed at their Southern California location. Development is led by their Co-founder and CTO, Mr. Daniel Baker. Daniel is known to be a savant code writer who began writing code at the age of 10 and is currently proficient in writing all languages of code. Daniel and his team are sometimes faced with insufficient laboratory Information Systems (LIS) in relation to the implementation of supportive end-to-end automation and “to date they have always been able to create custom code to overcome any and every challenge”, says CTO Daniel Baker. Req Right considers themselves a boutique technology partner and understand that each labs needs are unique and therefore they offer a set of free custom development hours per month with every plan.
Throughout the pandemic they continuously meet labs that feel stuck using inadequate systems due to fear of disruption. They understand the fear is caused by typically costly, slow, and inadequate implementation. Req Right has overcome that fear by offering a 10-day, non-disruptive implementation process. Their process involves connectivity to the labs LIS and extensive testing prior to pushing the labs new customized workflow system live. Once the system goes live their client’s staff is trained in just a few hours and then immediately begin to enjoy the benefits of being able to accommodate an unlimited number of clients and test site locations with customizable features for all unique locations needs.
Scaling with Req Right is simple, manageable, and compliant. Their clients have been scaling from inception and regularly use the system as a key tool in landing major accounts. You can learn more about Req Right at http://www.reqrightlabsoftware.com.
Share article on social media or email:
[ad_2]
[ad_1]
Joanne M. Conroy, MD, CEO and President of Dartmouth-Hitchcock and Dartmouth-Hitchcock Health
“The amount of money someone has in their bank account or their zip code shouldn’t be a barrier to receiving the best care possible.” – Dr. Conroy
WASHINGTON (PRWEB)
December 07, 2021
The Steven Schroeder Award for Outstanding Healthcare CEO was presented at The Leapfrog Group’s annual meeting. This year’s recipient was Joanne M. Conroy, MD, CEO and President of Dartmouth-Hitchcock (D-H) and Dartmouth-Hitchcock Health (D-HH) in New Hampshire.
The award was created by Costs of Care, a leading non-profit dedicated to building a pipeline of change agents to deliver more affordable health care, in conjunction with The Leapfrog Group, to recognize a hospital and/or health system CEO who has demonstrated courageous and ethical leadership addressing the twin issues of affordability and quality of health care in their community.
“We hope to inspire change in our health care system, and one way of doing that is celebrating positive examples of leadership in safety and affordability, like Dr. Conroy,” said Chris Moriates, MD, Executive Director of Costs of Care.
Dr. Conroy has led D-H and D-HH to achieve outstanding safety outcomes, avoid low-value care, and focus on financial assistance and transparency for patients. As CEO and president of New Hampshire’s only academic health system, Dr. Conroy has overseen significant positive changes, including a dramatic turnaround in the D-HH system’s financial performance, the announcement of two major new expansion projects, and a strategic planning process that will guide the organization into the future. The goal is to be trustworthy and to provide excellent care, while keeping costs down. The top-down support from Dr. Conroy has made it possible for D-HH to focus on quality improvement and the costs of care without sacrificing the highest level of care that each patient expects and receives.
The Outstanding Healthcare CEO award is named in honor of Steven Schroeder, MD, Distinguished Professor of Health and Health Care at the University of California San Francisco and former President and CEO of the Robert Wood Johnson Foundation. Dr. Schroeder has spent five decades inspiring and mentoring leaders to forcefully advocate for better quality and more affordable health care, and he has inspired leaders of both Costs of Care and The Leapfrog Group.
“Dr. Conroy is a courageous leader, demonstrating what’s possible when you provide sensible, high-quality care. Her leadership should be held in the highest regard and should serve as inspiration for health systems leaders across the country,” stated Dr. Schroeder.
“At the heart of what we do as healthcare providers is healing the sick and educating patients about how to live the healthiest lives they can, into the future. The amount of money someone has in their bank account or their zip code shouldn’t be a barrier to receiving the best care possible,” Dr. Conroy said. “Receiving the Schroeder Award is a really distinct honor for me, because I truly believe – and so does everyone on our teams at D-H – that we must have an unrelenting focus on safe, high-quality care for every patient. Without hesitation, I share this award with all D-HH employees, because it is our shared belief in this principle that makes delivering on that promise to our patients possible.”
Leah Binder, president and CEO of The Leapfrog Group said of Dr. Conroy, “she inspires us with her passion for quality and safety, her ethical approach to reducing waste in health care costs, and her national reputation for mentoring outstanding women in health care. The pandemic has not made it easy to run a health care system, but this award shows us the power of courageous and principled leadership to win the day in spite of enormous challenges.”
About Costs of Care
Costs of Care is a nonprofit organization dedicated to building a pipeline of change agents to deliver more affordable care. Since 2009, Costs of Care has collected more than 500 personal accounts from physicians, nurses, and patients all over the United States that illustrate routine and high yield opportunities to improve the value of care delivery through improved decision-making. Costs of Care has created widely adopted and enduring resources to educate medical trainees and clinicians about how to address health care costs and provide high-value care, including the textbook Understanding Value-Based Healthcare, the “COST” framework for designing value improvement projects, multiple workshops, and free, CME-approved video modules. In December 2019, Costs of Care launched the Affordability Moonshot – envisioning a world in which “no one has to choose between their life and their life-savings” – paired with an Affordability Accelerator in September 2021 to support and collaborate on promising ideas to improve patient affordability.
Connect at http://costsofcare.org, be a part of the Moonshot at moonshot.costsofcare.org, and follow on Twitter/Instagram @CostsOfCare.
About The Leapfrog Group
Founded in 2000 by large employers and other purchasers, The Leapfrog Group is a national nonprofit organization driving a movement for giant leaps forward in the quality and safety of American health care. The flagship Leapfrog Hospital Survey and new Leapfrog Ambulatory Surgery Center (ASC) Survey collect and transparently report hospital and ASC performance, empowering purchasers to find the highest-value care and giving consumers the lifesaving information they need to make informed decisions. The Leapfrog Hospital Safety Grade, Leapfrog’s other main initiative, assigns letter grades to hospitals based on their record of patient safety, helping consumers protect themselves and their families from errors, injuries, accidents, and infections.
Share article on social media or email:
[ad_2]
[ad_1]
The past 12 months have been a real struggle for so many businesses, and with the support of our amazing team and shared insatiable appetite for growth, Makers Nutrition has climbed to new heights, from client care to business strategy.
HAUPPAUGE, N.Y. (PRWEB)
December 07, 2021
Today, Makers Nutrition received the Business Intelligence Group’s BIG Award for Business and was named the 2021 Company of the Year. BIG’s annual program rewards companies, products and people that are leading their respective industries.
Makers Nutrition has been named the Business Intelligence Group Company of the Year for its major feat in the nutraceutical industry. This is Makers Nutrition’s 6th honor from Business Intelligence Group, from Best Place to Work to Excellence in Customer Service. Since 2018, the company has been recognized for its leadership in an ever-growing industry that looks to trailblazer such as Founder and CEO Jason Provenzano for innovation.
“This year, being named Company of the Year by Business Intelligence Group speaks volumes about our unrelenting commitment to our success and that of our clients,” said Mr. Provenzano. “The past 12 months have been a real struggle for so many businesses, and with the support of our amazing team and shared insatiable appetite for growth, Makers Nutrition has climbed to new heights, from client care to business strategy. We are truly honored to be named a winner in the 2021 BIG Awards for Business.”
“We are so proud to award Makers Nutrition for their outstanding 2021 leadership and achievements,” said Maria Jimenez, chief nomination officer of the Business Intelligence Group. “This year’s group of winners are clearly leading by example in the global business community.”
About Makers Nutrition
A two-time Inc. 5000 honoree, Makers Nutrition, is a groundbreaking manufacturer for dietary supplement companies worldwide. Specializing in capsules, tablets, powders, softgels and gummies, Makers Nutrition provides a full-service option for all contract manufacturing, graphic design, packaging, and fulfillment service needs.
About Business Intelligence Group
The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry award programs, business executives—those with experience and knowledge—judge the programs. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains and honors those companies whose achievements stand above those of their peers.
Share article on social media or email:
[ad_2]
